Almirall Upbeat Over Initial Sales Of Atopic Dermatitis Drug

Ebglyss sales, all from Germany, were €3.6m in the first quarter and while that may appear a little underwhelming at first glance, the Spanish drugmaker is impressed with the launch and its impact on dermatologists and patients.

Almirall
• Source: Almirall

Almirall SA has unveiled the first sales for its closely-watched atopic dermatitis drug Ebglyss and the Spanish firm is pleased with the initial launch data on a drug which will be key to the firm's future prospects.

Ebglyss (lebrikizumab), which obtained EU and UK approval at the end of 2023 for moderate-to-severe atopic dermatitis, had sales of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business